During tumor progression, T-cell-mediated antitumor response is significantly impaired, characterized by low secretion of interleukin-2 (IL-2), TNF-α, and interferon-γ (IFN-γ) and a high expression of inhibitory receptors such as PD-1 [90]. This evidence concerns the gene IL2 and neoplasm.